The discovery of the Philadelphia chromosome followed by identification of its BCR/ABL fusion gene product and the resultant constitutively active P210 BCR/ABL tyrosine kinase prompted the unravelling of the molecular pathogenesis of CML. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.